{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:31:14Z","timestamp":1758126674431,"version":"3.41.2"},"reference-count":28,"publisher":"Korean Cancer Association","issue":"3","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2023-CC140196"],"award-info":[{"award-number":["RS-2023-CC140196"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2025,7,15]]},"abstract":"<jats:p>Purpose Nausea and vomiting are major non-hematological adverse events associated with niraparib maintenance therapy. This study aimed to investigate the time-trend patterns of niraparib-induced nausea and vomiting (NINV) and the associated risk factors in patients with ovarian cancer.Materials and Methods In this prospective study, we enrolled patients with stage III-IV epithelial ovarian cancer who received niraparib as frontline maintenance therapy. The clinicopathological characteristics and time-trend patterns of patients with NINV were collected through in-person surveys and electronic medical records from the National Cancer Center.Results Of 53 patients, 50 (94.3%) were diagnosed with high-grade serous ovarian carcinoma. BRCA mutations and homologous recombination deficiency (HRD) were identifi ed in 23 (43.4%) and 32 (60.4%) patients, respectively. Thirty-one patients (58.5%) had NINV. Time-trend analyses revealed that the fi rst peak intensity of NINV was reached at 3 h post-dose, and the second peak intensity was reached at 11 hour post-dose. NINV signifi cantly decreased from week 1 to weeks 8 and 12. In multivariate analyses of risk factors for NINV, HRD-positive tumors (p &lt; 0.001) and prior experience of chemotherapy-induced nausea and vomiting (p=0.004) were associated with the occurrence of NINV.Conclusion Pre-emptive treatment with antiemetics is required to manage early-phase NINV during niraparib maintenance therapy in patients with risk factors. Additional larger studies are needed to confi rm these fi ndings and to develop optimal preventive strategies for NINV.<\/jats:p>","DOI":"10.4143\/crt.2024.899","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T02:19:57Z","timestamp":1730773197000},"page":"865-872","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Time-Trend Analysis and Risk Factors for Niraparib-Induced Nausea and Vomiting in Ovarian Cancer: A Prospective Study"],"prefix":"10.4143","volume":"57","author":[{"given":"Young Wook","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongkyu Eugene","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Ik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeong In","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2954","reference":[{"doi-asserted-by":"publisher","key":"ref1","DOI":"10.3322\/caac.21834"},{"doi-asserted-by":"publisher","key":"ref2","DOI":"10.4143\/crt.2019.139"},{"volume-title":"","year":"2024","key":"ref3"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.3802\/jgo.2017.28.e48"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.1016\/j.ejca.2022.11.029"},{"doi-asserted-by":"publisher","key":"ref6","DOI":"10.1056\/nejmoa1810858"},{"key":"ref7","first-page":"2391","volume-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","author":"Gonzalez-Martin","year":"2019"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.1007\/s11523-021-00841-2"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.1016\/j.clinthera.2024.01.004"},{"doi-asserted-by":"publisher","key":"ref10","DOI":"10.1016\/j.ygyno.2023.11.037"},{"doi-asserted-by":"publisher","key":"ref11","DOI":"10.1016\/j.ejca.2023.04.024"},{"doi-asserted-by":"publisher","key":"ref12","DOI":"10.3802\/jgo.2024.35.e3"},{"doi-asserted-by":"publisher","key":"ref13","DOI":"10.1200\/edbk_390876"},{"key":"ref14","first-page":"2154","volume-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","author":"Mirza","year":"2016"},{"doi-asserted-by":"publisher","key":"ref15","DOI":"10.1007\/s00520-015-2882-7"},{"doi-asserted-by":"publisher","key":"ref16","DOI":"10.21037\/apm-20-1784"},{"doi-asserted-by":"publisher","key":"ref17","DOI":"10.1007\/s00520-013-1843-2"},{"doi-asserted-by":"publisher","key":"ref18","DOI":"10.1001\/jamaoncol.2023.2283"},{"doi-asserted-by":"publisher","key":"ref19","DOI":"10.1007\/s40268-023-00448-0"},{"doi-asserted-by":"publisher","key":"ref20","DOI":"10.1007\/s40262-022-01167-6"},{"doi-asserted-by":"publisher","key":"ref21","DOI":"10.1093\/annonc\/mdy181"},{"doi-asserted-by":"publisher","key":"ref22","DOI":"10.18632\/oncotarget.1814"},{"doi-asserted-by":"publisher","key":"ref23","DOI":"10.1038\/s41598-020-59074-4"},{"doi-asserted-by":"publisher","key":"ref24","DOI":"10.1016\/j.ygyno.2024.03.009"},{"doi-asserted-by":"publisher","key":"ref25","DOI":"10.3389\/fonc.2021.724620"},{"doi-asserted-by":"publisher","key":"ref26","DOI":"10.1200\/po.22.00258"},{"doi-asserted-by":"publisher","key":"ref27","DOI":"10.2147\/cmar.s4739"},{"doi-asserted-by":"publisher","key":"ref28","DOI":"10.1161\/hypertensionaha.122.17947"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.899","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T01:51:19Z","timestamp":1752457879000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2024.899","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"type":"print","value":"1598-2998"},{"type":"electronic","value":"2005-9256"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"2024-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-04","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}